samedan logo

home > news > detailed info

Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients with HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer


Study Meets Primary Endpoint, Confirming the ADC [Vic-]Trastuzumab Duocarmazine (SYD985) is Superior to Physician’s Choice in Delaying Disease Progression

NIJMEGEN, The Netherlands, June 08, 2021 / B3C newswire / -- Byondis B.V. today announced positive topline results from the Phase III TULIP® study, a multi-center, open-label, randomized clinical trial. The trial compared the efficacy and safety of the company’s antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) to physician's choice treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).

The Phase III TULIP study “SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer” met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement over physician’s choice. PFS is defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurred earlier. The study also demonstrated preliminary supportive overall survival (OS) results.

“There is considerable unmet medical need in patients with HER2-positive metastatic breast cancer and [vic-]trastuzumab duocarmazine represents a promising potential clinical advance,” said Byondis Chief Medical Officer Jan Schellens, M.D., Ph.D. “We are excited by the topline results of TULIP and indebted to all patients who participated in the clinical studies.”

Byondis CEO Marco Timmers, Ph.D., referred to the study’s culmination as a triumph over adversity. “A large trial involving breast cancer patients with advanced disease is difficult in the best of times, but it is especially challenging during a global pandemic. The completion of TULIP is a testament to the dedication of all involved, especially the patients, their families and participating clinical sites.”

Detailed results from TULIP will be published at scientific conferences in due course. Byondis will complete the biological license application (BLA) and intends to submit it before the end of 2021.

With this positive study outcome, Byondis is planning to explore partnerships with pharma and biopharma companies in order to commercialize SYD985 and make it available to patients in need of new treatment options. SYD985 was granted fast track designation by the U.S. Food & Drug Administration in January 2018 based on promising data from heavily pre-treated last-line HER2-positive MBC patients participating in a two-part Phase I clinical trial (SYD985.001).(1)

1. Banerji, Udai, et al. “Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER2-Expressing Breast Cancer: a Phase 1 Dose-Escalation and Dose-Expansion Study.” The Lancet Oncology, Elsevier, 27 June 2019,
phone +31 (0)24 679 5100
email Byondis B.V. Microweg 22 P.O. Box 6570 6503 GB Nijmegen, the Netherlands
Print this page
Send to a friend
News and Press Releases

New inline coding solution for pharmaceutical blister packs

How Drop on Demand becomes the standard The new VDP 827 is a standardized inline Drop on Demand (DOD) solution for variable data printing on pharmaceutical blister packs. Many blister machine suppliers are now offering the solution as standard, and retrofits are possible as well. The VDP 827 is accelerating the retirement of embossing technology and offers greater economic benefits than other printing methods.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation


1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement